News
-
-
-
COMMUNIQUÉ DE PRESSE
VusionGroup - H1 2025 Results: Strong improvement in profitability - Raising Full Year guidance
VusionGroup reports strong financial performance in H1 2025: Revenue up 51%, adjusted EBITDA up 84%. Raises 2025 targets with €1.5 billion in revenue. CEO confident in digital transformation opportunities -
COMMUNIQUÉ RÉGLEMENTÉ
Déclaration hebdomadaire d'opérations effectuées du 8 au 12 septembre 2025
-
COMMUNIQUÉ RÉGLEMENTÉ
Disclosure of transactions in own shares from September 8 to September 12, 2025
-
-
-
COMMUNIQUÉ DE PRESSE
bonyf NV Showcases Innovative Product Portfolio at ExpoPharm 2025 in Düsseldorf
bonyf NV presents innovative product portfolio at ExpoPharm 2025 in Düsseldorf, showcasing patented solutions for oral, dental, and personal care. CEO Jean-Pierre Bogaert emphasizes focus on innovation and clinical efficacy -
COMMUNIQUÉ DE PRESSE
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Protagonist Therapeutics to present Phase 2b ANTHEM-UC study data on targeted oral peptide icotrokinra at UEGW Week 2025 in Berlin. Company focuses on advanced therapies in ulcerative colitis -